79 related articles for article (PubMed ID: 35442320)
1. SHOULD ROUTINE LIVER BIOPSY BE CONSIDERED IN BARIATRIC SURGICAL PRACTICE? AN ANALYSIS OF THE LIMITATIONS OF NON-INVASIVE NAFLD MARKERS.
Concon MM; Gestic MA; Utrini MP; Chaim FDM; Chaim EA; Cazzo E
Arq Gastroenterol; 2022; 59(1):110-116. PubMed ID: 35442320
[TBL] [Abstract][Full Text] [Related]
2. Compare the Combined Diagnostic Accuracy of Transient Elastography and Visual Liver Score in Assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Compare it with Liver Biopsy in Morbidly Obese Patients Undergoing Bariatric Surgery: An Observational Study.
Sharma D; Anand G; Meena S; Bhardwaj V
Obes Surg; 2024 Apr; 34(4):1247-1256. PubMed ID: 38411879
[TBL] [Abstract][Full Text] [Related]
3. A Validation Study of Non-invasive Scoring Systems for Assessing Severity of Hepatic Fibrosis in a Cohort of South Indian Patients With Non-alcoholic Fatty Liver Disease.
Mathew JF; Panackel C; Jacob M; Ramesh G; John N
J Clin Exp Hepatol; 2024; 14(5):101407. PubMed ID: 38699513
[TBL] [Abstract][Full Text] [Related]
4. Fibrotic NASH in Individuals with Obesity: a Cross-sectional Analysis of the Prevalence of this Significant Milestone of Disease Progression and Accuracy of a Non-invasive Marker for its Screening.
de Souza Echeverria L; Mounzer DLS; Gestic MA; Utrini MP; Chaim FDM; Callejas-Neto F; Chaim EA; Cazzo E
Obes Surg; 2024 Feb; 34(2):389-395. PubMed ID: 38110785
[TBL] [Abstract][Full Text] [Related]
5. Identification of Predictors of Non-alcoholic Steatohepatitis and Its Severity in Individuals Undergoing Bariatric Surgery.
Ayres ABS; Carneiro CRG; Gestic MA; Utrini MP; Chaim FDM; Callejas-Neto F; Chaim EA; Cazzo E
Obes Surg; 2024 Feb; 34(2):456-466. PubMed ID: 38097891
[TBL] [Abstract][Full Text] [Related]
6. Performance of non-invasive tests for liver fibrosis resolution after bariatric surgery.
Raverdy V; Tavaglione F; Chatelain E; Caiazzo R; Saponaro C; Lassailly G; Verkindt H; Baud G; Marciniak C; Chetboun M; Oukhouya-Daoud N; Gnemmi V; Leteurtre E; Duhamel A; Philippe M; Marot G; Romeo S; Pattou F
Metabolism; 2024 Apr; 153():155790. PubMed ID: 38219973
[TBL] [Abstract][Full Text] [Related]
7. Association of the Non-Alcoholic Fatty Liver Disease Fibrosis Score with subclinical myocardial remodeling in patients with type 2 diabetes: A cross-sectional study in China.
Fan N; Ding X; Zhen Q; Gu L; Zhang A; Shen T; Wang Y; Peng Y
J Diabetes Investig; 2021 Jun; 12(6):1035-1041. PubMed ID: 33030804
[TBL] [Abstract][Full Text] [Related]
8. Association of Histopathological and Biochemical Aspects of NAFLD With the Severity of Liver Fibrosis in Individuals With Obesity: Cross-sectional Study.
Carneiro CRG; Ayres ABS; Gestic MA; Utrini MP; Chaim FDM; Callejas-Neto F; Chaim EA; Cazzo E
Obes Surg; 2024 May; 34(5):1569-1574. PubMed ID: 38502518
[TBL] [Abstract][Full Text] [Related]
9. Application of artificial intelligence techniques for non-alcoholic fatty liver disease diagnosis: A systematic review (2005-2023).
Zamanian H; Shalbaf A; Zali MR; Khalaj AR; Dehghan P; Tabesh M; Hatami B; Alizadehsani R; Tan RS; Acharya UR
Comput Methods Programs Biomed; 2024 Feb; 244():107932. PubMed ID: 38008040
[TBL] [Abstract][Full Text] [Related]
10. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.
Dulai PS; Sirlin CB; Loomba R
J Hepatol; 2016 Nov; 65(5):1006-1016. PubMed ID: 27312947
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review.
Amoroso M; Augustin S; Moosmang S; Gashaw I
J Mol Med (Berl); 2024 May; ():. PubMed ID: 38753041
[TBL] [Abstract][Full Text] [Related]
12. TyG-GGT is a Reliable Non-Invasive Predictor of Advanced Liver Fibrosis in Overweight or Obese Individuals.
Jin L; Gu J; Zhang Z; Du CF; Xu FQ; Huang XK; Gao ZY; Li Y; Yu LL; Zhang X; Ru GQ; Liu JW; Liang L; Sun XD; Xiao ZQ
Obes Surg; 2024 Apr; 34(4):1333-1342. PubMed ID: 38427150
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
Dalbeni A; Lombardi R; Henrique M; Zoncapè M; Pennisi G; Petta S; Tateishi R; Keklikkiran C; Colecchia A; Sacerdoti D; Mantovani A; Ravaioli F
Hepatology; 2024 May; 79(5):1107-1116. PubMed ID: 37976417
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.
Uslusoy HS; Nak SG; Gülten M
World J Hepatol; 2011 Aug; 3(8):219-27. PubMed ID: 21954411
[TBL] [Abstract][Full Text] [Related]
15. Risk Stratification of Advanced Fibrosis in Patients With Human Immunodeficiency Virus and Hepatic Steatosis Using the Fibrosis-4, Nonalcoholic Fatty Liver Disease Fibrosis, and BARD Scores.
Yendewa GA; Khazan A; Jacobson JM
Open Forum Infect Dis; 2024 Feb; 11(2):ofae014. PubMed ID: 38379565
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and outcome of sarcopenia in non-alcoholic fatty liver disease.
Giri S; Anirvan P; Angadi S; Singh A; Lavekar A
World J Gastrointest Pathophysiol; 2024 Apr; 15(1):91100. PubMed ID: 38682026
[TBL] [Abstract][Full Text] [Related]
17. Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study.
Miller H; Harman D; Aithal GP; Manousou P; Cobbold JF; Parker R; Sheridan D; Newsome PN; Karpe F; Neville M; Arlt W; Sitch AJ; Korbonits M; Biehl M; Alazawi W; Tomlinson JW
BMJ Open; 2024 Jan; 14(1):e074918. PubMed ID: 38238179
[TBL] [Abstract][Full Text] [Related]
18. Gene-by-Environment Interaction in Non-Alcoholic Fatty Liver Disease and Depression: The Role of Hepatic Transaminases.
Manusov EG; Diego VP; Abrego E; Herklotz K; Almeida M; Mao X; Laston S; Blangero J; Williams-Blangero S
Med Res Arch; 2023 Sep; 11(9):. PubMed ID: 38698891
[TBL] [Abstract][Full Text] [Related]
19. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.
Barritt AS; Watkins S; Gitlin N; Klein S; Lok AS; Loomba R; Schoen C; Reddy KR; Trinh HN; Mospan AR; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal AJ
Hepatol Commun; 2021 Jun; 5(6):938-946. PubMed ID: 34141981
[TBL] [Abstract][Full Text] [Related]
20. Benchmarking clinical risk prediction algorithms with ensemble machine learning: An illustration of the superlearner algorithm for the non-invasive diagnosis of liver fibrosis in non-alcoholic fatty liver disease.
Charu V; Liang JW; Mannalithara A; Kwong A; Tian L; Kim WR
medRxiv; 2023 Aug; ():. PubMed ID: 37577485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
